US biotechnology company, Moderna, entered the clinical test for the messenger ribonucleic (mRNA) vaccine against four influenza strains: A(H1N1), A(H3N2), B/Yamagata and B/Victoria.
The firm planned to jab 180 American adults for Phase 1/2 to assess the safety and strength of the immune response to the multi-strain shot, called mRNA-1010, which is patterned on the Moderna’s COVID-19 doses.
Unlike the current flu vaccines, it utilized mRNA technology to send genetic molecules containing the code of the virus to the human body.
According to the World Health Organization (WHO), there are around three to five million severe flu cases worldwide and 290,000 to 650,000 flu-related deaths.
Moreover, Moderna prepares to work on potential vaccine combinations against flu, SARS-CoV-2, respiratory syncytial virus (RSV), and human metapneumovirus (hMPV) after they successfully produced a coronavirus vaccine that has more than 90 percent effectivity.
As of now, the efficacy of the flu shot is approximately 40 to 60 percent.
Comments